INSIGHTS ON CLINICAL TRIAL PARTNERING

• Targeted Protein Degraders: Transforming Oral Therapeutics

  CDMOs play a critical role in TPD development by offering specialized infrastructure and analytical capabilities to support the transition from preclinical research to clinical supply and commercialization.

• Increasing Efficiency And Reducing Drug Waste

  Discover how streamlined clinical supply chain management helped accelerate study timelines, reduce costs, and support global treatment delivery through a strategic technology partnership.

• Bringing Clinical Trials To Everyone's Backyard

  Learn how bringing clinical trials to any community around the world is not only possible but also increases patient access and reach and improves recruitment and retention.

• Developing Community-Based And Trial-Naïve Sites: The Real ROI

  Trial-naïve sites, when supported with infrastructure, training, and network integration, represent a critical yet underused opportunity to expand patient access and accelerate recruitment.

• Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy

  9/25/2025

  Hereditary transthyretin amyloidosis (ATTRv) is very rare, prompting a Phase 1 trial of in vivo CRISPR/Cas9 gene editing to reduce mutant protein and stop cardiomyopathy progression.

• Canadian CTA Frequently Asked Questions

  2/20/2024

  This FAQ list offers clarity on pivotal aspects of your drug development journey, ensuring studies in Canada pave the way for U.S. FDA and EMA submissions.

• The Defensiveness Trap In Vendor Selection And Management

  8/22/2025

  In clinical research, sponsor–vendor relationships are often framed as negotiations. Yet while both sides want to achieve a successful study, the process often becomes a tug-of-war.

• 5 Myths About Patient Payments In Clinical Trials

  10/8/2025

  Digital payment solutions debunk myths around clinical trial compensation, improving participant retention, easing site burden, and enabling smoother global operations through faster, more reliable payments.

• Critical Imaging Risks In GLP-1 And Neurology Studies

  4/3/2025

  In the evolving landscape of GLP-1 and neurology clinical trials, imaging has become a pivotal tool for evaluating both efficacy and safety. Delve into the early indicators of imaging-related challenges and insights into preclinical strategies for effective risk mitigation.